Press Room

News / Oct 30, 2019

Hovione’s innovative solutions nominated for CPhI awards 2019

Learn more about the innovations from our scientists

Hovione is nominated for CPhI awards 2019 being shortlisted in two categories:

 

1. “API Development”, for its PRIME tool - Process Ranking of Inputs from Manufacturing.

 

cphi-awards-2019-prime

 

“It is an honour to have been selected for the finalists’ panel, which is already by itself an achievement. The PRIME tool enables to grow our collective knowledge on chemical processes and being able to visualize how each project is evolving along the lifecycle according to several metrics; additionally, we can establish thresholds for different metrics according to our past knowledge and develop our process to meet those targets. We can also start to build automatically databases for e.g. the most frequent reaction conditions per type of reaction. The tool not only helps managing better our knowledge on chemical processes but also adds a lot of value for our customers” said Filipe Ataíde, PhD, one of Hovione’s scientists responsible for PRIME.

 

2. “Analysis, Testing, and Quality Control” for its Accelerated dissolution methods for extended release drug product.

 

cphi-awards-2019-dissolution

 

“Extended release formulations provide many advantages to patients and greatly simplify treatment but carry a heavy burden in terms of quality control. The methodology presented here aims at reducing the burden on the quality control lab, by developing accelerate dissolution methods that shorten the API release duration from several months to a few days. This accelerates the analysis timing and still guarantees the quality of the drug product since a good correlation with the long-term API release is the base of this development. Most importantly, this development poses a very significant advantage in terms of patient compliance, particularly for drugs where administration is complex such as those administered through the ocular route, or when the risk of missing a dose is high, and also regarding drugs with a frequent administration for extended periods. Above all, it contributes to the patients’ well-being” said Mafalda Paiva, MsC, one of Hovione’s scientists responsible for this innovation.

 

 

Also in the Press Room